Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
REVIEW PAPER
The role of T-lymphocytes in primary Sjögren syndrome
Online publication date: 2012-03-02
Reumatologia 2012;50(1):45-51
KEYWORDS
ABSTRACT
Sjögren syndrome is a disease of the connective tissue with an autoimmune basis in the course of which chronic, progressing inflammatory processes in the lacrimal and salivary glands lead to the impediment of their secretory function, causing dryness of the eyes and the oral cavity; organ symptoms occur much more rarely. We can distinguish between primary and secondary Sjögren syndrome, which occur alongside other autoimmune diseases. Many cells of the immune system are involved in the not yet fully explored pathomechanism of Sjögren syndrome. Beyond doubt, type T lymphocytes play a significant role in the development of Sjögren syndrome, especially in local inflammation (Table I). Besides the cells of the immunological system, cytokines, chemotactic factors and adhesion molecules as well as apoptosis play an important role in the pathomechanism of the development of Sjögren syndrome. Acquiring precise understanding of the role of T lymphocytes is crucial for explaining the pathomechanism of this disease as well as for introducing more targeted and effective methods of therapy, including biological agents.
REFERENCES (29)
1.
Fox PC. Autoimmune diseases and Sjögren’s syndrome – an autoimmune exocrinopathy. Oral-Based Diagnostics 2007; 1098: 15-21. .
2.
Jonsson R, Vogelsang P, Volchenkov R, et al. The complexity of Sjögren’s syndrome: Novel aspects on pathogenesis. In: Immunology Letters, Elselvier 2011. .
3.
Lee BH, Tudares MA, Nguyen CQ. Sjögren’s syndrome: an old tale with a new twist. Arch Immunol Ther Exp 2009; 57: 57-66. .
4.
Nikolov NP, Illei GG. Pathogenesis of Sjögren’s syndrome. Curr Opin Rheumatol 2009; 21: 465-470. .
5.
Gottenberg JE. Primary Sjögren’s syndrome: pathophysiological, clinical and therapeutic advances. Joint Bone Spine 2009; 76: 591-594. .
6.
Hansen A, Lipsky PE, Dorner T. Immunopathogenesis of primary Sjögren’s syndrome: implications for disease management and therapy. Curr Opin Rheumatol 2005; 17: 558-565. .
7.
Katsifis GE, Moutsopoulos NM, Wahl SM. T lymphocytes in Sjögren’s syndrome: contributors to and regulators of pathophysiology. Clin Rev Allergy Immunol 2007; 32: 252-264. .
8.
Pijpe J, van Imhoff GW, Vissink A, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren’s syndrome and associated MALT lymphoma. Ann Rheum Dis 2005; 64: 958-960. .
9.
Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjögren’s syndrome – one-year followup. Arthritis Rheum 2002; 46: 3301-3303. .
10.
Mariette X, Ravaud P, Steinfeld S, et al. Infliximab in primary Sjögren’s syndrome: open extension 2 of the TRIPSS study in 64 patients. Arthritis Rheum 2004; 50: S574-S575. .
11.
Varin M-M, Le Pottier L, Youinou P, et al. B-cell tolerance breakdown in Sjögren’s Syndrome: Focus on BAFF. Autoimmun Rev 2010; 9: 604-608. .
12.
Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun 2010; 34: 400-407. .
13.
Salomonsson S, Jonsson MV, Skarstein K, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren’s syndrome. Arthritis Rheum 2003; 48: 3187-3201. .
14.
Xanthou G, Tapinos NI, Polihronis M, et al. CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjögren’s syndrome. Clin Exp Immunol 1999; 118: 154-163. .
15.
Skopouli FN, Fox PC, Galanopoulou V, et al. T-cell subpopulations in the labial minor salivary-gland histopathologic lesion of Sjögren syndrome. J Rheumatol 1991; 18: 210-214. .
16.
Esch TR. Pathogenetic factors in Sjögren’s syndrome: Recent developments. Critical Rev Oral Biol Med 2001; 12: 244-251. .
17.
Szodoray P, Gal I, Barath S, et al. Immunological alterations in newly diagnosed primary Sjögren’s syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines. Scand J Rheum 2008; 37: 205-212. .
18.
Wakefield D, Palladinetti P, Tedla N, et al. Chemokine expression in primary Sjögren’s syndrome. Invest Ophthalmol Vis Sci 1999; 40: S553-S573. .
19.
Pflugfelder SC, Jones D, Ji ZH, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren’s syndrome keratoconjunctivitis sicca. Curr Eye Res 1999; 19: 201-211. .
20.
Roescher N, Tak PP, Illei GG. Cytokines in Sjögren’s syndrome: potential therapeutic targets. Ann Rheum Dis 2010; 69: 945-948. .
21.
Katsifis GE, Rekka S, Moutsopoulos NM, et al. Systemic and local interleukin-17 and linked cytokines associated with Sjögren’s syndrome immunopathogenesis. Am J Pathol 2009; 175: 1167-1177. .
22.
Fox RI, Kang HI, Ando D, et al. Cytokine messenger – RNA expression in salivary-gland biopsies of Sjögren’s syndrome. J Immunol 1994; 152: 5532-5539. .
23.
Kolkowski EC, Reth P, Pelusa F, et al. Th1 predominance and perforin expression in minor salivary glands from patients with primary Sjögren’s syndrome. J Autoimmunity 1999; 13: 155-162. .
24.
Hagiwara E, Pando J, Ishigatsubo Y, Klinman DM. Altered frequency of type 1 cytokine secreting cells in the peripheral blood of patients with primary Sjögren’s syndrome. J Rheumatol 1998; 25: 89-93. .
25.
Hunger RE, Muller S, Laissue JA, et al. Inhibition of submandibular and lacrimal gland infiltration in nonobese diabetic mice by transgenic expression of soluble TNF-receptor p55. J Clin Invest 1996; 98: 954-961. .
26.
Azuma M, Motegi K, Aota K, et al. Role of cytokines in the destruction of acinar structure in Sjögren’s syndrome salivary glands. Lab Invest 1997; 77: 269-280. .
27.
Gottenberg JE, Lavie F, Abbed K, et al. CD4 CD25(high) regulatory T cells are not impaired in patients with primary Sjögren’s syndrome. J Autoimmunity 2005; 24: 235-242. .
28.
Christodoulou MI, Kapsogeorgou EK, Moutsopoulos NM, Moutsopoulos HM. Foxp3(+) T-Regulatory Cells in Sjögren’s Syndrome Correlation with the Grade of the Autoimmune Lesion and Certain Adverse Prognostic Factors. Am J Pathol 2008; 173: 1389-1396. .
29.
Sarigul M, Yazisiz V, Bassorgun CI, et al. The numbers of Foxp3(+) Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjögren’s syndrome. Lupus 2010; 19: 138-145.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
